Pasithea Therapeutics Corp. Warrant (KTTAW)
NASDAQ (CM) NASDAQ (CM) Primary Summary
KTTAW Chart
Pasithea Therapeutics Corp. Warrant Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Anthony Scaramucci SkyBridge Capital II LLC | 50,000 | $39,999.24 | $405 | -$39,594.24 | -98.99% |
 Jae Cho Marex Group plc | 25,000 | $450 | $177.5 | -$272.5 | -60.56% |
Pasithea Therapeutics Corp. Warrant (KTTAW) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Pasithea Therapeutics Corp. Warrant ever had a stock split?
Pasithea Therapeutics Corp. Warrant Profile
| Biotechnology Industry | Healthcare Sector | Tiago Reis Marques CEO | NASDAQ (CM) Exchange | 70261F111 CUSIP |
| US Country | 5 Employees | - Last Dividend | - Last Split | 15 Sep 2021 IPO Date |
Overview
Pasithea Therapeutics Corp. is a pioneering biotechnology company that specializes in researching and discovering innovative treatments for Central Nervous System disorders, RASopathies, and a broad spectrum of other diseases. Operating through two main segments, Therapeutics and Clinics, the company not only focuses on the development of novel therapeutic candidates but also provides crucial business support services to anti-depression clinics, healthcare entities, and registered healthcare providers across the board. Founded in 2020 with its headquarters in Miami Beach, Florida, Pasithea Therapeutics Corp. is at the forefront of addressing some of the most challenging medical conditions with cutting-edge biotechnological approaches.
Products and Services
PAS-004
Leading the company's dynamic portfolio is PAS-004, a next-generation mitogen-activated protein kinase (MEK) inhibitor that boasts a macrocyclic design. This innovative product candidate aims to provide treatment for a variety of RASopathies, which include neurofibromatosis type 1 and Noonan syndrome. In addition, PAS-004 shows promising potential for applications in lamin A/C cardiomyopathy and various oncology indications, demonstrating Pasithea's commitment to tackling complex diseases with advanced therapeutic solutions.
PAS-003
Another significant candidate within Pasithea's pipeline is PAS-003. This product is in development for the treatment of amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. Through the advancement of PAS-003, Pasithea aims to contribute meaningfully to the ALS treatment landscape, offering hope to patients and families affected by this devastating condition.
PAS-002
PAS-002 is being developed with the objective to treat multiple sclerosis (MS), a chronic illness that affects the central nervous system, leading to a range of symptoms including physical, mental, and sometimes psychiatric problems. By focusing on this candidate, Pasithea Therapeutics Corp. underscores its dedication to battling neurodegenerative diseases and improving the quality of life for individuals living with MS.
PAS-001
Rounding out Pasithea's product pipeline is PAS-001, a therapeutic candidate aimed at treating schizophrenia. This condition, characterized by episodes of psychosis including delusions and hallucinations, significantly affects a person's ability to discern reality. Through the development of PAS-001, Pasithea Therapeutics Corp. aspires to offer new, effective treatment options to those afflicted by schizophrenia, further emphasizing the company’s focus on central nervous system disorders.
